Skip to main content

Table 2 The associations of SHR and GV with mortality in patients with or without diabetes

From: Simultaneous assessment of stress hyperglycemia ratio and glycemic variability to predict mortality in patients with coronary artery disease: a retrospective cohort study from the MIMIC-IV database

 

Continuous

Categorical

Per 1-unit increment

Tertile 1

Tertile 2

Tertile 3

In-hospital mortality

Overall

 SHR

    

  Unadjusted

2.288 (1.835–2.854)‡

1.000

0.849 (0.483–1.492)

3.508 (2.256–5.453)‡

  Model 1

3.023 (2.314–3.950)‡

1.000

1.086 (0.551–2.143)

5.564 (3.246–9.537)‡

  Model 2

2.149 (1.557–2.967)‡

1.000

1.011 (0.493–2.071)

3.948 (2.185–7.136)‡

 GV

    

  Unadjusted

1.021 (1.012–1.031)‡

1.000

2.531 (1.492–4.292)‡

3.651 (2.200−6.057)‡

  Model 1

1.023 (1.012–1.034)‡

1.000

2.736 (1.473–5.083)†

3.963 (2.176–7.218)‡

  Model 2

1.019 (1.006–1.032)‡

1.000

1.671 (0.860–3.248)

2.468 (1.288–4.728)†

Patients without diabetes

 SHR

    

  Unadjusted

4.556 (3.161–6.568)‡

1.000

0.536 (0.225–1.276)

3.818 (1.965–7.418)‡

  Model 1

5.111 (3.406–7.670)‡

1.000

0.516 (0.190–1.404)

4.802 (2.302–10.015)‡

  Model 2

3.063 (1.931–4.860)‡

1.000

0.414 (0.141–1.212)

2.992 (1.316–6.804)†

 GV

    

  Unadjusted

1.044 (1.029–1.058)‡

1.000

4.516 (2.119–9.628)‡

11.825 (5.610−24.925)‡

  Model 1

1.043 (1.028–1.059)‡

1.000

5.213 (2.100-12.936)‡

15.104 (6.192–36.842)‡

  Model 2

1.039 (1.019–1.059)‡

1.000

3.770 (1.413–10.057)†

8.714 (3.262–23.283)‡

Patients with diabetes

 SHR

    

  Unadjusted

1.544 (1.146–2.081)†

1.000

1.440 (0.684–3.033)

3.047 (1.663–5.582)‡

  Model 1

1.992 (1.361–2.917)‡

1.000

2.344 (0.913–6.021)

6.031 (2.694–13.498)‡

  Model 2

1.603 (0.991–2.595)

1.000

1.993 (0.703–5.650)

5.334 (2.151–13.227)‡

 GV

    

  Unadjusted

1.001 (0.985–1.017)

1.000

1.064 (0.501–2.261)

1.108 (0.551–2.228)

  Model 1

0.998 (0.978–1.019)

1.000

1.042 (0.437–2.482)

0.946 (0.411–2.175)

  Model 2

0.996 (0.972–1.021)

1.000

0.657 (0.236–1.828)

0.796 (0.303–2.096)

1-year mortality

Overall

 SHR

    

  Unadjusted

1.639 (1.457–1.845)‡

1.000

0.941 (0.713–1.242)

2.155 (1.700−2.731)‡

  Model 1

1.972 (1.716–2.265)‡

1.000

1.084 (0.785–1.498)

2.683 (2.031–3.544)‡

  Model 3

1.470 (1.239–1.745)‡

1.000

0.928 (0.665–1.295)

1.726 (1.279–2.330)‡

 GV

    

  Unadjusted

1.017 (1.012–1.023)‡

1.000

1.687 (1.287–2.210)‡

2.271 (1.755–2.939)‡

  Model 1

1.019 (1.012–1.025)‡

1.000

1.710 (1.245–2.348)‡

2.396 (1.764–3.253)‡

  Model 3

1.014 (1.007–1.022)‡

1.000

1.450 (1.046–2.010)*

1.991 (1.427–2.777)‡

Patients without diabetes

 SHR

    

  Unadjusted

2.273 (1.835–2.815)‡

1.000

0.799 (0.531–1.203)

1.882 (1.301–2.721)‡

  Model 1

2.718 (2.174–3.397)‡

1.000

0.968 (0.596–1.569)

2.617 (1.705–4.018)‡

  Model 3

2.070 (1.572–2.725)‡

1.000

0.762 (0.464–1.251)

1.644 (1.039–2.599)*

 GV

    

  Unadjusted

1.030 (1.023–1.038)‡

1.000

2.096 (1.460–3.011)‡

4.089 (2.832–5.904)‡

  Model 1

1.030 (1.023–1.038)‡

1.000

2.161 (1.408–3.318)‡

4.615 (2.998–7.105)‡

  Model 3

1.028 (1.019–1.038)‡

1.000

1.824 (1.173–2.836)†

3.459 (2.190–5.463)‡

Patients with diabetes

 SHR

    

  Unadjusted

1.445 (1.244–1.678)‡

1.000

1.213 (0.823–1.787)

2.476 (1.814–3.378)‡

  Model 1

1.680 (1.393–2.026)‡

1.000

1.390 (0.890–2.171)

2.926 (2.017–4.246)‡

  Model 3

1.244 (0.975–1.588)

1.000

1.052 (0.665–1.666)

1.714 (1.138–2.582)†

 GV

    

  Unadjusted

1.005 (0.996–1.013)

1.000

1.056 (0.703–1.587)

1.161 (0.798–1.689)

  Model 1

1.002 (0.991–1.013)

1.000

0.990 (0.616–1.591)

1.073 (0.688–1.673)

  Model 3

1.003 (0.991–1.014)

1.000

0.967 (0.597–1.566)

1.171 (0.739–1.855)

  1. Model 1: adjusted for age, female, and body mass index
  2. Model 2: adjusted for Model 1 plus heart rate, acute myocardial infarction, chronic heart failure, peripheral vascular disease, cerebrovascular disease, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, vasoactive drugs, insulin, other antidiabetic drugs, renal replacement therapy, ventilation, and estimated glomerular filtration rate
  3. Model 3: adjusted for Model 1 plus diastolic blood pressure, heart rate, acute myocardial infarction, hypertension, diabetes, chronic heart failure, peripheral vascular disease, cerebrovascular disease, antiplatelets, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, insulin, other antidiabetic drugs, renal replacement therapy, ventilation, and estimated glomerular filtration rate
  4. *P < 0.05, †P < 0.01, ‡P < 0.001